OpuholiŽenskoj Reproduktivnoj Sistemy | |
The first experience with intraabdominal chemotherapy in patients with disseminated ovarian cancer | |
V. V. Kuznetsov1  I. V. Panichenko1  S. A. Tyulyandin1  V. Yu. Buidenok1  A. S. Tyulyandina1  M. B. Stenina1  K. I. Zhordania1  | |
[1] N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow; | |
关键词: ovarian cancer; intraabdominal chemotherapy; paclitaxel; cisplatin; | |
DOI : 10.17650/1994-4098-2011-0-3-99-104 | |
来源: DOAJ |
【 摘 要 】
Ovarian cancer (OC) is characterized by its late diagnosis, mainly local tumor dissemination within the abdomen and small pelvis, and a relatively high susceptibility to drug therapy . Intraabdominal chemotherapy (CT) allows the higher intraabdominal drug concentrations to be produced as compared to systemic CT and, according to the data of some investigations, improves the results of treatment in a few patients with minimal tumor foci. In this connection, it is urgent to master the procedure of intraperitoneal CT, including to pl ace an intraabdominal port, to elaborate a regimen, and to determine the spectrum of its toxicity and safety.Subjects and methods. The paper gives the preliminary results of a pilot trial using intraabdominal CT in 8 patients with disseminated OC and fallopian tubes who have undergone optimal-volume surgical interventions in stage 1. All the patients received CT by the scheme: intravenous paclitaxel (135 mg/m 2) on day 1, intraabdominal cisplatin (75 mg/m 2) on day 2, and intraabdominal paclitaxel (60 mg/m 2) on day 8. A total of 6 courses were scheduled.Results. At the analysis of the results, 5 out the 8 patients received all the scheduled courses of CT, 3 patients continued treatment, including 1 patient in whom the intraabdominal port w as removed after the first course of CT because of significant fibrosis along the in traabdominal catheter, thereafter she continued to be treated by the standard intravenous scheme. Among local toxicity signs, there was a preponderance of grades 1–2 abdominal pains occurring after the intraabdominal administrations of chemotherapy preparations. Systemic toxicity, including hematological one, was moderate; in any cases it did not cause life-threatening complications or lead to the increase of course intervals or to the refusal of intraabdominal CT. At a median follow-up of 10.2 months (range 1.9–24.7 months or more), one patient w as found to have disease progression 12 months of therapy termination.
【 授权许可】
Unknown